; Whereas access to mifepristone remains a lifeline for millions of Americans who seek reproductive health care; Whereas, on April 7, 2023, the United States District Court for the Northern District of Texas issued an injunction that stayed the FDA’s approval of mifepristone; and Whereas, on April 7, 2023, the United States District Court for the Eastern District of Washington issued an injunction that preliminarily enjoined the FDA to refrain from making changes to its approval of mifepristone in the plaintiffs’ States of Arizona, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Michigan, Minnesota, Nevada, New Mexico, Oregon, Pennsylvania, Rhode Island, Vermont, and Washington, and the District of Columbia: Now, therefore, be it